Vision & Mission
Combining cancer vaccines
and T-cell therapies
ErVaccine Technologies develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies based on the identification of new families of tumor antigens.
We are dedicated to discover more accurate tumor epitopes that are shared between patients. We focus on non-conventional epitopes derived from endogenous retroviruses (HERVs).
Our approach is based on new bioinformatics algorithms to identify potential epitopes that are validated by proteomics and immunology assays: from bioinformatics to proteomics.